RESIST-TB conducted a webinar on 14 April 2022 on the latest results in the recent studies reporting on pretomanid-containing regimens, ZeNiX and TB-PRACTECAL, for the treatment of multidrug-resistant TB (MDR-TB).
Video recording of the webinar is now available online and can be accessed here.